Sim Ming Ann, Tham Yih Chung, Nusinovici Simon, Quek Ten Cheer, Yu Marco, Xue Can Can, Chee Miao Li, Peng Qing Sheng, Tan Eugene S J, Chan Siew Pang, Cai Yuan, Chong Eddie Jun Yi, Tan Boon Yeow, Venketasubramanian Narayanaswamy, Hilal Saima, Lai Mitchell K P, Choi Hyungwon, Richards Arthur Mark, Cheng Ching-Yu, Chen Christopher L H
Memory Aging and Cognition Centre, Departments of Pharmacology and Psychological Medicine, National University of Singapore, Singapore, Singapore.
Department of Anesthesia, National University Health System and National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore.
Alzheimers Dement. 2025 Mar;21(3):e14601. doi: 10.1002/alz.14601.
The utility of retinal photography-derived aging biomarkers for predicting cognitive decline remains under-explored.
A memory-clinic cohort in Singapore was followed-up for 5 years. RetiPhenoAge, a retinal aging biomarker, was derived from retinal photographs using deep-learning. Using competing risk analysis, we determined the associations of RetiPhenoAge with cognitive decline and dementia, with the UK Biobank utilized as the replication cohort. The associations of RetiPhenoAge with MRI markers(cerebral small vessel disease [CSVD] and neurodegeneration) and its underlying plasma proteomic profile were evaluated.
Of 510 memory-clinic subjects(N = 155 cognitive decline), RetiPhenoAge associated with incident cognitive decline (subdistribution hazard ratio [SHR] 1.34, 95% confidence interval [CI] 1.10-1.64, p = 0.004), and incident dementia (SHR 1.43, 95% CI 1.02-2.01, p = 0.036). In the UK Biobank (N = 33 495), RetiPhenoAge similarly predicted incident dementia (SHR 1.25, 95% CI 1.09-1.41, p = 0.008). RetiPhenoAge significantly associated with CSVD, brain atrophy, and plasma proteomic signatures related to aging.
RetiPhenoAge may provide a non-invasive prognostic screening tool for cognitive decline and dementia.
RetiPhenoAge, a retinal aging marker, was studied in an Asian memory clinic cohort. Older RetiPhenoAge predicted future cognitive decline and incident dementia. It also linked to neuropathological markers, and plasma proteomic profiles of aging. UK Biobank replication found that RetiPhenoAge predicted 12-year incident dementia. Future studies should validate RetiPhenoAge as a prognostic biomarker for dementia.
视网膜摄影衍生的衰老生物标志物在预测认知衰退方面的效用仍未得到充分探索。
对新加坡一个记忆门诊队列进行了5年的随访。RetiPhenoAge是一种视网膜衰老生物标志物，通过深度学习从视网膜照片中得出。使用竞争风险分析，我们确定了RetiPhenoAge与认知衰退和痴呆症之间的关联，并将英国生物银行用作复制队列。评估了RetiPhenoAge与MRI标志物（脑小血管疾病[CSVD]和神经退行性变）及其潜在血浆蛋白质组学特征的关联。
在510名记忆门诊受试者中（N = 155名认知衰退患者），RetiPhenoAge与新发认知衰退（亚分布风险比[SHR] 1.34，95%置信区间[CI] 1.10 - 1.64，p = 0.004）和新发痴呆症（SHR 1.43，95% CI 1.02 - 2.01，p = 0.036）相关。在英国生物银行（N = 33495）中，RetiPhenoAge同样预测了新发痴呆症（SHR 1.25，95% CI 1.09 - 1.41，p = 0.008）。RetiPhenoAge与CSVD、脑萎缩以及与衰老相关的血浆蛋白质组学特征显著相关。
RetiPhenoAge可能为认知衰退和痴呆症提供一种非侵入性的预后筛查工具。
在一个亚洲记忆门诊队列中研究了视网膜衰老标志物RetiPhenoAge。RetiPhenoAge越高，预测未来认知衰退和新发痴呆症的可能性越大。它还与神经病理学标志物以及衰老的血浆蛋白质组学特征相关。英国生物银行的复制研究发现RetiPhenoAge可预测12年后的新发痴呆症。未来的研究应验证RetiPhenoAge作为痴呆症预后生物标志物的有效性。
